FGI-104

Content sourced from Wikipedia, licensed under CC BY-SA 3.0.

FGI-104 is an experimental broad-spectrum antiviral drug. It works by blocking TSG101, a human protein that helps transport new virus particles out of infected cells, which disrupts the virus replication cycle.

The drug has shown activity against a range of viruses in studies, including hepatitis B, hepatitis C, HIV, Ebola virus, and Venezuelan equine encephalitis virus.

In preclinical tests, FGI-104 protected mice from Ebola virus disease, providing early evidence of potential antiviral effects in animals.

FGI-104 is not yet approved for use and is classified in the United States as an Investigational New Drug, indicating it is being studied in early development.